Clinical Trial Update: Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study of TAK-733 in adults with advanced nonhematologic malignancies has completed enrollment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• TAK-733

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Advanced Non-hematologic Malignancies, Advanced Metastatic Melanoma | Phase 1 | Status: COMPLETED